DE-CSC
7.11.2022 09:01:39 CET | Business Wire | Press release
CSC announced today that it will complete the acquisition of Intertrust Group, as set out in further detail in the joint press release issued by CSC and Intertrust Group. The acquisition marks an important milestone for CSC, which now will do business with more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands®, and more than 70% of the PEI 300. Rod Ward III, who is a direct descendant of one of the company’s two founders and has served as president and CEO of CSC for almost 13 years, will lead the combined organization. A highly experienced Enterprise Leadership Team, including Intertrust Group CEO Shankar Iyer, will support Ward.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005033/en/
(Graphic: Business Wire)
Founded in 1899 and based in Wilmington, Delaware, CSC is one of the nation’s “Top Workplaces” and prides itself on being privately held and professionally managed for more than 120 years. “This acquisition is about bringing together the complementary expertise, capabilities, and geographic scope of CSC and Intertrust Group to allow us to better serve our clients’ global business administration and compliance needs,” says Ward. “We’re creating a combined organization that will enable us to provide the industry-leading service our clients expect, as evidenced by our Net Promoter Scores.”
“Our acquisition of Intertrust Group will allow us to navigate the ever-changing compliance and regulatory environment that our clients face, thanks to a world-class combination of people, processes, and technology solutions,” adds Ward. “Our clients will also benefit from being served by a stable strategic partner that has been in business under common ownership for more than a century.”
“We have a long history of success in acquiring and integrating companies in a manner that benefits both our clients and our employees. Our employees appreciate not only our stability, which comes from CSC being a private company with a strong financial foundation and long-term perspective, but also our passion for working with each other to best serve our clients,” says Ward. “Today, we’re pleased to welcome the talented workforce of Intertrust Group into the CSC family, and we’re excited to embark on this next chapter together.”
“We have always been impressed with CSC’s strong client-first reputation,” says Iyer. “We believe the market will benefit greatly from the combination of two of the leading providers of corporate, fund, and compliance solutions.”
“Through this combination,” adds Iyer, “we have realized an outcome that is a true win for every stakeholder and, most importantly, the best outcome for our colleagues at Intertrust.”
As one company, CSC and Intertrust Group will have the combined expertise of more than 7,500 dedicated employees with capabilities across more than 140 jurisdictions. “This means we can provide a “follow the sun” service, helping our clients wherever they need us to be,” says Ward.
About CSC
CSC is the trusted partner of choice for more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands®, and more than 70% of the PEI 300. We are the world’s leading provider of global business administration and compliance solutions, specialized administration services to alternative asset managers across a range of fund strategies, transactions involving capital markets participants in both public and private markets, domain name system management and digital brand and fraud protection, and corporate tax software solutions. Founded in 1899 and headquartered in Wilmington, Delaware, USA, CSC prides itself on being privately held and professionally managed for more than 120 years. CSC has office locations and capabilities in more than 140 jurisdictions across Europe, the Americas, Asia Pacific, and the Middle East. We are a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. We are the business behind business®. Learn more at cscglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 15:22:00 CEST | Press release
Healthcare and life sciences leaders are advancing AI with caution—fragmentation, capability gaps, and execution challenges are slowing enterprise-wide impact AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design a
JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 15:00:00 CEST | Press release
International Olympic Committee and JPMorganChase Announce Landmark Global Olympic Partnership The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support t
BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 15:00:00 CEST | Press release
BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
